Skip to Main Content

Paper Details

Targeting residual inflammatory risk: The next frontier for atherosclerosis treatment and prevention.
0
2023
LDLC, atherosclerosis, atherosclerotic, cardiovascular death, cholesterol, colchicine, hsCRP, hyperlipidemia, myocardial infarction, patients, statin, stroke
Author NameAffiliation
Paul M RidkerFrom the Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital
  • 1 - 1

Datasets

Release 1.2